Opinion
Video
Author(s):
John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.
Video content above is prompted by the following questions:
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC
2 Commerce Drive
Cranbury, NJ 08512